Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2022 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from _____ to _____ Commission File Number: 001-35020 INFUSYSTEM HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 20-33414 ...

InfuSystem Holdings Inc. (NYSE:INFU) Q3 2022 Earnings Conference Call November 8, 2022 9:00 AM ET Company Participants Joe Dorame - IR, Lytham Partners Rich DiIorio - CEO Barry Steele - CFO Cary Lachance - President and Chief Operating Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Alex Nowak - Craig-Hallum Capital Group Jim Sidoti - Sidoti & Company Aaron Warwick - Breakout Investors Operator Good day, and welcome to the InfuSystem Holdings, Inc. Reports Third Quarter Fisc ...

Enabling Continuity of Care for Patients, From the Clinic to Their Home Investor Presentation SEPTEMBER 8, 2022 l (NYSE American: INFU) Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Certain statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements relating to future actions, business plans, objectives an ...

InfuSystem Holdings Inc. (NYSE:INFU) Q2 2022 Earnings Conference Call August 4, 2022 9:00 AM ET Company Participants Joe Dorame - IR, Lytham Partners Rich DiIorio - CEO Barry Steele - CFO Conference Call Participants Brooks O'Neil - Lake Street Capital Jim Sidoti - Sidoti & Company Operator Good day and welcome to the InfuSystem Holdings Incorporated Reports Second Quarter Fiscal Year 2022 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2022 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from _____ to _____ (I.R.S. Employer Identification No.) Commission File Number: 001-35020 3851 West Hamlin Road Rochester Hills, Michigan 48309 (Address of ...

Enabling Continuity of Care for Patients, From the Clinic to Their Home Investor Presentation March 23, 2022 l (NYSE American: INFU) Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Certain statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements relating to future actions, business plans, objectives and p ...

Financial Data and Key Metrics Changes - Revenue for Q1 2022 totaled $26.8 million, representing a 9% increase from the prior year quarter and slightly ahead of Q4 2021 revenue of $26.5 million [30] - Operating cash flow increased by 54% compared to the prior year, demonstrating strong cash flow characteristics [6][45] - Adjusted EBITDA for Q1 2022 was $4.1 million, or 15.5% of net revenue, which was $2 million lower than Q1 2021 and $2.4 million lower sequentially from Q4 2021 [35] Business Line Data and Key Metrics Changes - The DME business grew revenue by 18%, significantly contributing to the overall revenue growth [6] - Integrated Therapy Services (ITS) platform saw a growth of 5% with a solid gross margin of 64.5% [18] - Pain Management and Wound Care delivered 13% revenue growth for Q1 2022, with Pain Management treating a record number of patients in March [19] Market Data and Key Metrics Changes - The company signed a three-year master service agreement with GE Healthcare, expected to generate approximately $10 million to $12 million in annual revenue [15] - The agreement allows the company to provide biomed services in 1,200 medical facilities, including 800 hospital systems in the U.S. and Canada [15] Company Strategy and Development Direction - The company is focused on expanding its biomedical services business and increasing its reach into acute care markets [16][24] - The strategic investments made in the previous year are expected to strengthen the company and enhance future growth potential [23] - The company aims to leverage the new GE Healthcare relationship to capitalize on significant growth opportunities in biomed and DME [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential of the business, supported by solid momentum in ITS and DME platforms [23] - The company anticipates revenue growth of 15% to 20% for the full year 2022, with adjusted EBITDA expected to be between $24 million and $27 million [26][39] - Management acknowledged potential risks, including COVID-19 surges and supply chain disruptions, but remains optimistic about achieving revenue targets [40][41] Other Important Information - The company repurchased approximately $4 million of its common shares, indicating confidence in its stock value [25][44] - The liquidity position remains strong, with available liquidity totaling $39.8 million at the end of the quarter [45] Q&A Session Summary Question: Growth assumptions for ITS and DME - Management indicated that growth will be split roughly evenly between ITS and DME, with DME benefiting significantly from the GE agreement [54] Question: Run rate expectations for Pain and Wound Care - The combined run rate for Pain and Wound Care is expected to approach $20 million in annual revenue by the end of the year [57] Question: Potential for additional products under the GE agreement - The master service agreement with GE allows for the addition of new products and services, with potential for significant revenue growth [60] Question: Hiring challenges in the current labor market - Management noted that while hiring has become more challenging, they have been successful in retaining talent and filling positions [70][72] Question: Future cash flow and stock repurchase plans - Management expressed that cash flow is expected to remain strong, with a focus on investing in the business rather than prioritizing stock buybacks [81][82]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2022 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from _____ to _____ Commission File Number: 001-35020 INFUSYSTEM HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 20-3341405 ( ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K _____________________________________________________________ x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR o ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to ___________________ Commission File Number: 001-35020 ______________________ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Delaware 20-3341405 (State or Other Jurisdiction of Incorporation or Organization) for the transition period from _____ to _____ (I.R.S. Employer Identification No.) Commission File Number: 001-35020 x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 INFUSYSTEM HOLDINGS, INC. 3851 ...